Ramtin MD - RenovoRx Chairman Founder

All Insiders . USA . 
Stock . RenovoRx . Stakeholders . Insider . Ramtin MD
RNXT Stock  USD 1.26  0.10  7.35%   

Insider

Ramtin MD is Chairman Founder of RenovoRx
Age 58
Address 4546 El Camino Real, Los Altos, CA, United States, 94022
Phone650 284 4433
Webhttps://renovorx.com

RenovoRx Management Efficiency

The company has return on total asset (ROA) of (0.7008) % which means that it has lost $0.7008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5512) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.58 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.63). At this time, RenovoRx's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 4.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.4 M in 2024.
RenovoRx currently holds 4.47 M in liabilities. RenovoRx has a current ratio of 9.81, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about RenovoRx's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Susan MSEliem Therapeutics
N/A
Kristin AinsworthSeres Therapeutics
N/A
Lorenz MullerMilestone Pharmaceuticals
60
MBA MDIkena Oncology
59
Peter RhodeHCW Biologics
66
MD BALumos Pharma
69
Jo PalmerPhillipsEliem Therapeutics
N/A
Kimberly SheehanMilestone Pharmaceuticals
N/A
RAC SakaiTempest Therapeutics
N/A
Lisa MillerLumos Pharma
N/A
Petpiboon PrasitTempest Therapeutics
N/A
Lori CPALumos Pharma
40
BBA CPALumos Pharma
57
FACC MDMilestone Pharmaceuticals
60
Jeffrey EcsedyIkena Oncology
54
Erin LavelleEliem Therapeutics
47
Jeff NelsonMilestone Pharmaceuticals
43
Bradley JDLumos Pharma
45
Michelle ZhangIkena Oncology
N/A
Alfredo CastroIkena Oncology
N/A
Anne MoonTempest Therapeutics
N/A
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Renovorx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. RenovoRx (RNXT) is traded on NASDAQ Exchange in USA. It is located in 4546 El Camino Real, Los Altos, CA, United States, 94022 and employs 8 people. RenovoRx is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-1.55
Return On Asset-0.7

RenovoRx Leadership Team

Elected by the shareholders, the RenovoRx's board of directors comprises two types of representatives: RenovoRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RenovoRx. The board's role is to monitor RenovoRx's management team and ensure that shareholders' interests are well served. RenovoRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RenovoRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ronald CPA, VP Controller
James Ahlers, Chief Officer
Leesa Gentry, Senior Operations
Angela Nelms, Chief Officer
Ryan Witt, Senior Partnerships
Ramtin MD, Chairman Founder
CGMA CPA, Controller VP
Shaun Bagai, Secretary CEO

RenovoRx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RenovoRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.55
Return On Asset-0.7
Current Valuation23.08 M
Shares Outstanding24 M
Shares Owned By Insiders1.90 %
Shares Owned By Institutions8.18 %
Number Of Shares Shorted86.95 K
Price To Book4.62 X
EBITDA(11.4 M)
Net Income(10.23 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for RenovoRx Stock Analysis

When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY